Patent intelligence · US
US 6514537
Magnesium citrate solution
Magnesium citrate solution
Patent details — US 6514537
- Jurisdiction
- US
- Status
- expired
- Grant date
- Feb 4, 2003
- Expiration
- Jan 30, 2023
- Applicant
- Cumberland Swan Holdings, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/191, A61K33/06, A61K33/08
Quick answer
US 6514537 (Magnesium citrate solution) is held by Cumberland Swan Holdings, Inc.. Status: expired. Granted Feb 4, 2003. Expires Jan 30, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cumberland Swan Holdings, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/191, A61K33/06, A61K33/08, A61K45/06
More from Cumberland Swan Holdings, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12161632
Compositions and methods of treating cardiac fibrosis with ifetroban
granted -
US 11806400
Injectable ibuprofen formulation
granted -
US 11571412
Thromboxane receptor antagonists in AERD/asthma
granted -
US 10925860
Compositions and methods of treating cardiac fibrosis with ifetroban
granted -
US 10751383
Doses and methods for administering telavancin
granted -
US 10583126
Compositions and methods of treating cardiac fibrosis with ifetroban
granted -
US 10456380
Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists
granted -
US 10314824
Compositions and methods of treating cardiac fibrosis with ifetroban
granted
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 6514537?
US 6514537 (Magnesium citrate solution) is held by Cumberland Swan Holdings, Inc.. Status: expired. Granted Feb 4, 2003. Expires Jan 30, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6514537?
Cumberland Swan Holdings, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.
When does US 6514537 expire?
Our index shows an expiration date of Jan 30, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.